GLP‑1s Suppress Multiple Addictions

A recent study reported in a major medical journal links GLP‑1 anti‑obesity drugs with reduced risks across alcohol, cannabis, cocaine, nicotine, and opioid abuse. If causal, that transforms GLP‑1s from weight medicines into broad 'wanting' modulators with implications for addiction treatment, food markets, and social behavior. — If replicated and causal, this would reshape public‑health priorities, regulatory coverage decisions, and cultural debates about pharmaceutical interventions in desire and consumption.